WASHINGTON—The investigational oral drug amiselimod outperformed placebo at controlling mild to moderate ulcerative colitis symptoms with no safety signals in a phase 2 trial.
Amiselimod (Bausch) is a sphingosine 1-phosphate receptor modulator, much like the FDA-approved UC medications ozanimod (Zeposia, Celgene) and etrasimod (Velsipity, Pfizer). However, “amiselimod is an S1P receptor modulator without dose titration,” explained investigator Stephen B. Hanauer, MD, a